{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:55:15Z","timestamp":1776318915882,"version":"3.50.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biologics and targeted therapies are a first-line treatment option for individuals with Crohn\u2019s disease (CD). Nevertheless, clinical remission rates vary considerably among different biologics and targeted therapies. This study aims to develop and validate a predictive nomogram for the response to biologics and targeted therapy in individuals with CD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included individuals with CD admitted to the First People\u2019s Hospital of Wuhu from January 2020 to June 2025. Clinical remission rates at 14 and 26 weeks were observed. The clinical remission rates of different biologics and targeted therapy were analyzed using the chi-square test, and multiple comparisons were performed. The least absolute contraction and selection operator (LASSO) regression algorithm was used to determine variables related to clinical remission. A nomogram model was constructed, and the model performance was assessed utilizing receiver operating characteristic (ROC) curves, calibration curves, and decision curves (DCA). Internal validation was performed using repeated sampling and Harrell\u2019s concordance index (C-index).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>218 patients were included in the study. Compared with other biologics, upadacitinib (UPA) had the highest clinical remission rate at week 26 (94.1%,16\/17subjects). Nine variables were identified by LASSO regression, including pre-treatment Crohn\u2019s disease activity index (CDAI), disease duration, smoking history, disease site, disease behavior, perianal lesions, hemoglobin (Hb), erythrocyte sedimentation rate (ESR), and type of biologic. The area under the curve (AUC value) was 0.796. The calibration curve and DCA curve showed good calibration and clinical applicability. The internal validation also demonstrated moderate discriminative performance, with a C-index of 0.74.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The study results demonstrate that UPA appears to show a significant clinical remission rate in a small cohort, but this finding needs to be validated in a larger-scale study. Furthermore, a practical tool has been developed to help clinicians identify the treatment response to biologics and targeted therapy in CD patients, promoting the development of personalized treatment and precision medicine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1788290","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:25:11Z","timestamp":1776317111000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a predictive nomogram for response to biologics and targeted therapy in Crohn\u2019s disease: a retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Ping","family":"Lin","sequence":"first","affiliation":[{"name":"The Department of Gastroenterology, The First People\u2019s Hospital of WuHu","place":["Wuhu, Anhui, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"The Department of Gastroenterology, The First People\u2019s Hospital of WuHu","place":["Wuhu, Anhui, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Zhou","sequence":"additional","affiliation":[{"name":"The Department of Gastroenterology, The First People\u2019s Hospital of WuHu","place":["Wuhu, Anhui, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[{"name":"The Department of Gastroenterology, The First People\u2019s Hospital of WuHu","place":["Wuhu, Anhui, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[{"name":"The Department of Gastroenterology, The First People\u2019s Hospital of WuHu","place":["Wuhu, Anhui, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1186\/s12876-025-04070-z","article-title":"Development and validation of a nomogram for predicting endoscopic healing in Crohn's disease patients receiving infliximab treatment","volume":"25","author":"Li","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.disamonth.2017.07.001","article-title":"A comprehensive review and update on Crohn's disease","volume":"64","author":"Gajendran","year":"2018","journal-title":"Dis Mon"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz028","article-title":"Prospective study of psychological morbidity and illness perceptions in young people with inflammatory bowel disease","volume":"13","author":"Brooks","year":"2019","journal-title":"J Crohns Colitis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s00423-012-1030-9","article-title":"Inflammatory bowel disease","volume":"113","author":"Wehkamp","year":"2016","journal-title":"Dtsch Arztebl Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/1756283x09357579","article-title":"Optimal use of biologics in the management of Crohn's disease","volume":"3","author":"Panaccione","year":"2010","journal-title":"Therap Adv Gastroenterol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12876-024-03403-8","article-title":"Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-na\u00efve and bio-experienced Crohn's disease patients: a retrospective multicenter study","volume":"24","author":"Na","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/17562848241290663","article-title":"Effectiveness comparison between ustekinumab and infliximab for Crohn's disease complicated with intestinal stenosis: a multicenter real-world study","volume":"17","author":"He","year":"2024","journal-title":"Therap Adv Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.36469\/001c.88947","article-title":"Evaluation of treatment patterns and maintenance dose titration among patients with Crohn's disease initiating biologics with 3 years of follow-up","volume":"10","author":"Zhao","year":"2023","journal-title":"J Health Econ Outcomes Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i43.6710","article-title":"First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: a 2020 Delphi consensus","volume":"26","author":"Alkhatry","year":"2020","journal-title":"World J Gastroenterol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000003222","article-title":"2023 Chinese national clinical practice guideline on diagnosis and management of Crohn's disease","volume":"137","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2017.15.4.434","article-title":"Medication adherence in inflammatory bowel disease","volume":"15","author":"Chan","year":"2017","journal-title":"Intest Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2057582","article-title":"Factors associated with poor compliance amongst hospitalized, predominantly adolescent pediatric Crohn's disease patients","volume":"54","author":"Cohen","year":"2022","journal-title":"Ann Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/17562848241256237","article-title":"Development and validation of a novel therapeutic drug monitoring-based nomogram for prediction of primary endoscopic response to anti-TNF therapy in active Crohn's disease","volume":"17","author":"Chen","year":"2024","journal-title":"Therap Adv Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251382749","article-title":"Machine learning-based prediction of response to ustekinumab with Crohn's disease","volume":"18","author":"Xiong","year":"2025","journal-title":"Therap Adv Gastroenterol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2024.2422352","article-title":"Analysis and validation of diagnostic biomarkers and immune cell infiltration characteristics in Crohn's disease by integrating bioinformatics and machine learning","volume":"57","author":"Ren","year":"2024","journal-title":"Autoimmunity"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/ede.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: a framework for traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.11.025","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"350","author":"Collins","year":"2015","journal-title":"Bmj"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.19723\/j.issn.1671-167x.2021.03.01","article-title":"Economic burden and factors associated with Crohn's disease","volume":"53","author":"Zhou","year":"2021","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2043655","article-title":"The impact of symptom severity on the humanistic and economic burden of inflammatory bowel disease: a real-world data linkage study","volume":"38","author":"Naegeli","year":"2022","journal-title":"Curr Med Res Opin"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/s0016-5085(24)03783-1","article-title":"Real-world effectiveness and safety of upadacitinib in Crohn's disease: a multicenter study","volume":"23","author":"Devi","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf138","article-title":"Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn's disease: 2-year results from the U-ENDURE long-term extension study","volume":"19","author":"Loftus","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.70291","article-title":"Induction efficacy and safety of upadacitinib for active Crohn's disease in Japanese patients: a multicenter retrospective study","volume":"9","author":"Saiki","year":"2025","journal-title":"JGH Open"},{"key":"B24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/flgastro-2024-102668","article-title":"Real-world effectiveness of upadacitinib in Crohn's disease: a UK multicentre retrospective cohort study","volume":"15","author":"Elford","year":"2024","journal-title":"Frontline Gastroenterol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac078","article-title":"Real-world short-term effectiveness of ustekinumab in Crohn's disease: results from a multicenter, prospective study in China","volume":"28","author":"Cao","year":"2022","journal-title":"Inflammation Bowel Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac269","article-title":"Real-world evidence of effectiveness and safety of vedolizumab for inflammatory bowel disease in Taiwan: a prospective nationwide registry (VIOLET) study","volume":"29","author":"Lin","year":"2023","journal-title":"Inflammation Bowel Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/14712598.2023.2185510","article-title":"Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study","volume":"23","author":"Mocci","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/17562848211023386","article-title":"Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study","volume":"14","author":"Eriksson","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/ecco-jcc\/jjz195","article-title":"Predictors of primary response to biologic treatment [Anti-TNF, vedolizumab, and ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice","volume":"14","author":"Gisbert","year":"2020","journal-title":"J Crohns Colitis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.579","article-title":"The natural history of adult Crohn's disease in population-based cohorts","volume":"105","author":"Peyrin-Biroulet","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v31.i18.104206","article-title":"Role of serological biomarkers in evaluating and predicting endoscopic activity in inflammatory bowel disease","volume":"31","author":"Liu","year":"2025","journal-title":"World J Gastroenterol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae176","article-title":"Developing a machine-learning prediction model for infliximab response in Crohn's disease: integrating clinical characteristics and longitudinal laboratory trends","volume":"31","author":"Qiu","year":"2025","journal-title":"Inflammation Bowel Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.7754\/clin.lab.2022.221034","article-title":"Risk prediction model for Crohn's disease based on hematological indicators","volume":"69","author":"Zeng","year":"2023","journal-title":"Clin Lab"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3390\/children9101558","article-title":"Prognostic factors of biologic therapy in pediatric IBD","volume":"9","author":"Buczy\u0144ska","year":"2022","journal-title":"Children (Basel)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13044","article-title":"Combining pharmacometric models with predictive and prognostic biomarkers for precision therapy in Crohn's disease: a case study of brazikumab","volume":"12","author":"Zhang","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/sga.0000000000000572","article-title":"Effectiveness of a telephone-based motivational intervention for smoking cessation in patients with Crohn disease: a randomized, open-label, controlled clinical trial","volume":"44","author":"Navarro Correal","year":"2021","journal-title":"Gastroenterol Nurs"},{"key":"B37","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/apt.14550","article-title":"Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease","volume":"47","author":"Barr\u00e9","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa214","article-title":"Body mass index does not impact clinical efficacy of ustekinumab in Crohn's disease: a Post Hoc analysis of the IM-UNITI trial","volume":"27","author":"Wong","year":"2021","journal-title":"Inflammation Bowel Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40259-022-00522-0","article-title":"Impact of obesity on response to biologic therapies in patients with inflammatory bowel diseases","volume":"36","author":"Bassi","year":"2022","journal-title":"BioDrugs"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz080","article-title":"Long-term clinical effectiveness of ustekinumab in patients with Crohn's disease who failed biologic therapies: a national cohort study","volume":"13","author":"Liefferinckx","year":"2019","journal-title":"J Crohns Colitis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab050","article-title":"Results of the seventh scientific workshop of ECCO: precision medicine in IBD-disease outcome and response to therapy","volume":"15","author":"Verstockt","year":"2021","journal-title":"J Crohns Colitis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1788290\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:25:12Z","timestamp":1776317112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1788290\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2026.1788290"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1788290","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"article-number":"1788290"}}